Inclusion Criteria:

- All patients must have histological evidence of a solid malignant tumor
(hematological malignancies are excluded) with convincing clinical, radiographic or
isotopic evidence of cancer, for which no effective proven treatment exists. CNS
associated tumors are preferred, but not required. Patients must sign an informed
consent that complies with the investigator/DEKK-TEC policies and approved by a Human
Investigation Review Committee.

- All patients must have a projected survival time of at least 12 weeks and a Karnofsky
performance score: >60% (or Zubrod score of >2).

- All patients must be off previous chemo- and/or radiotherapy for at least three (3)
weeks prior to entrance into the study and have recovered from any toxic effects
induced by such treatment(s). Patients who have received a nitrosourea type drug
must have had no treatment within the last six weeks.

- Measurable lesions are not required for admittance to the study - but are desirable.

- Age initiated after limitation - 18 years or older. A separate pediatric study is
proposed to evaluate tolerance to the drug in children.

- Gender is not a criterion.

Exclusion Criteria:

- Hematology WBC <4,000 mm3 Platelets <100,000 mm3

- Liver Function If bilirubin, AST, and/or ALT are >ULN

- Renal Function Creatinine >1.5 mg%

- Cardiovascular Acute myocardial infarction Congestive heart failure - (NYHA criteria
for uncontrolled) Clinically significant cardiac arrhythmias - uncontrolled

- Concomitant chemotherapy or radiotherapy is not permitted.

- Pregnant or lactating females are excluded. Women of childbearing age, and their
sexual partners, must use an effective contraception program. Males who are having
sexual relations with women capable of child bearing must use birth control while on
the study and for 3-months after the last dose of the study drug.

- Allergies to eggs, lecithin or soy products.